Alkermes PLC (STU:8AK)
€ 22.2 -0.4 (-1.77%) Market Cap: 3.75 Bil Enterprise Value: 3.41 Bil PE Ratio: 9.49 PB Ratio: 3.24 GF Score: 68/100

Alkermes Plc at Bank of America Merrill Lynch Healthcare Conference (Virtual) Transcript

May 13, 2020 / 01:40PM GMT
Release Date Price: €13.01 (-4.76%)
Jason Matthew Gerberry
BofA Merrill Lynch, Research Division - MD in US Equity Research

Good day, everybody. My name is Jason Gerberry. I cover specialty pharma and biotech at Bank of America. I am pleased to be introducing our next company presenter, Alkermes, and CEO, Richard Pops. Alkermes is -- we all know Alkermes as a neuroscience-focused company although the company has some interesting developments in its pipeline in the oncology space. The company recently provided its first quarter update and some of the implications around the COVID-19 pandemic. So maybe Richard, I don't know -- to start, I don't know if you have any prepared remarks or if you want to provide any color just on sort of the 1Q update and how COVID-19 is impacting your business, and then we can jump into more specific questions from there.

Richard F. Pops
Alkermes plc - Chairman & CEO

Yes. I'll make a couple of remarks, Jason. First, I'll say good morning, and I hope you and the folks in your firm are well. It is a remarkable time. And we were just saying before we got on the call

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot